In the relentless pursuit of improved prostate cancer management, understanding and targeting AR-Vs, given the availability of a non-invasive blood-based AR-V7 test, is a necessary step toward addressing therapeutic resistance and improving patient outcomes. This evidence concerns the gene AR and prostate carcinoma.